



Review Article

Protein-kinase Inhibitors: A New Treatment Pathway for Autoimmune and Inflammatory Diseases? ☆



Diana Hernández-Flórez, Lara Valor*

Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain

ARTICLE INFO

Article history:

Received 9 March 2015

Accepted 26 June 2015

Available online 28 February 2016

Keywords:

Protein-kinase
Tyrosine-kinase
Kinase inhibitors
Intracellular signaling
Autoimmunity
Inflammation
Tofacitinib

Palabras clave:

Proteínas-cinasas
Tirosinas-cinasas
Inhibidores de las tirosinas-cinasas
Vías de señalización intracelular
Autoinmunidad
Inflamación
Tofacitinib

ABSTRACT

Although advances in biological medicine have seen significant progress in the treatment of autoimmune and inflammatory disease, many patients do not experience a satisfactory response. Hence, there are two challenges facing the medical research community. The first is to continue development in the field of existing biological therapies, such as monoclonal antibodies. The second is to open new frontiers of research and explore treatment alternatives for non-responders to other therapies. Attention has increasingly turned to the therapeutic potential of small molecule weight kinase inhibitors (SMKIs), currently used extensively in oncology and hematology. Initial research into the therapeutic value of SMKIs for autoimmune and inflammatory diseases has been encouraging. SMKIs are taken orally, which reduces cost for the health provider, and could increase compliance for the patient. This is why research is now focusing increasingly on SMKIs as a new generation line of treatment in these diseases. Tofacitinib, an inhibitor of Janus-kinase, is currently the only drug approved for the treatment of rheumatoid arthritis by FDA. However, much more needs to be done to understand the intracellular signaling pathways and how these might affect disease progression before solid conclusions can be drawn.

© 2015 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Los inhibidores de las proteínas-cinasas en enfermedades autoinmunes e inflamatorias: presente y futuro de nuevas dianas terapéuticas

RESUMEN

Pese a los avances terapéuticos en las enfermedades autoinmunes e inflamatorias, muchos pacientes no logran un control adecuado de la enfermedad. De ahí la necesidad de optimizar el uso de las terapias biológicas y de explorar nuevas opciones terapéuticas. La disponibilidad de fármacos que inhiben proteínas-cinasas ya es una realidad en especialidades como oncología y hematología, donde los resultados asociados a la evolución clínica de la enfermedad han sido prometedores. La principal ventaja de estos fármacos es la administración oral, que podría favorecer la adherencia del paciente y reducir los costes asociados al tratamiento. Tofacitinib, inhibidor de tirosinas-cinasas, actualmente es el único fármaco de esta categoría aprobado para el tratamiento de la artritis reumatoide por la FDA. Estas dianas terapéuticas son evaluadas actualmente en diversas enfermedades autoinmunes e inflamatorias. Sin embargo, el conocimiento y la comprensión de las vías de señalización intracelular siguen siendo limitados, persistiendo dudas en cuanto al mecanismo de acción, la eficacia y los posibles efectos secundarios asociados al uso de estos nuevos fármacos.

© 2015 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Todos los derechos reservados.

☆ Please cite this article as: Hernández-Flórez D, Valor L. Los inhibidores de las proteínas-cinasas en enfermedades autoinmunes e inflamatorias: presente y futuro de nuevas dianas terapéuticas. Reumatol Clin. 2016;12:91–99.

* Corresponding author.

E-mail address: lvalor.hugum@salud.madrid.org (L. Valor).

Introduction

Until a little over 10 years ago, the therapeutic options for the treatment of diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), spondyloarthropathies (SA), psoriasis (PsO) and inflammatory bowel disease (IBD)—primarily Crohn's disease (CD) and ulcerative colitis (UC)—were very limited. At the present time, there is a wide spectrum of therapeutic options, including monoclonal antibodies to interleukins (IL), IL receptors, antigen recognition receptors and intercellular communication.¹ Recently, protein kinases (PK) have emerged as therapeutic targets for the treatment of these diseases, which has led to the development of inhibitors that block the activity of these proteins.² All this has contributed to deepen our knowledge of the immune mechanisms underlying the disease and the therapeutic response.

Protein Kinases: Definition and Function Relative to Autoimmunity and Inflammation

Protein kinases are enzymes that modify other proteins and/or enzymes biochemically, activating or deactivating them, depending on the objective of the intracellular communication from the membrane toward the nucleus. The sequencing of the human genome and advances in proteomics have enabled the identification of more than 500 PK, which have been cataloged in a system referred to as the “human kinome”.³ Depending on their cellular location and function, PK have been classified into 7 major groups, which include the tyrosine kinases (TK). Tyrosine kinases are enzymes that serve as mediators between the reception of an extracellular signal and the occurrence of an effector response. Their activation is produced by the phosphorylation or transfer of phosphate groups to the hydroxyl group of the tyrosine residues of the enzyme.⁴

The catalytic activity of PK is exhibited with: (a) *redundancy*: an action or response can be catalyzed by the simultaneous activation of separate enzymes; (b) *pleiotropy*: the activation of a single enzyme can promote different cell responses; and (c) *synergy*: the activation of several signaling pathways is necessary to achieve a specific effect and, thus, proper cell communication and function.

Yet, where within the framework of the immune system do PK fit in? The complex function of the cells of the immune system depends in part on the PK because of their decisive role in the cell signaling processes of growth, maturation, differentiation, migration, inflammation, aging and apoptosis. Thus, it is essential that PK activation be efficient, specific and appropriate, since defects in the activation and regulation of these mechanisms can affect the endocrine system and/or promote the development of malignant and/or anomalous cell phenotypes, as in cancer and autoimmunity.^{2,5,6}

What Does the Intracellular Signaling Process Involve?

As we mentioned above, the objective of intracellular signaling is to produce a nuclear response to the reception of a stimulus that is recognized by the cell membrane receptors. Protein kinases can form part of these receptors or be associated with the cell membrane, as they comprise 2 types: receptors with intrinsic kinase activity and receptors that have no intrinsic kinase activity but are associated with the kinases in their cytoplasmic domain.⁷

This signaling process can be summarized as follows:

(a) Recognition of different cytokines—chemokines, interleukins, growth factors or antigens—on the part of the specific receptors found on the cytoplasmic membrane.

- (b) Binding of this receptor to the stimulus that induces conformational changes in the receptor and adjacent proteins.
- (c) These conformational changes promote the activation of the kinases and, in the case of TK, the phosphorylation of its tyrosine residues.
- (d) The activation of the kinases triggers that of other proteins to create a cascade directed toward the cell nucleus
- (e) The start of gene transcription for protein synthesis, or the initiation of cellular processes such as cell differentiation, maturation, proliferation and apoptosis. This can be accompanied by the synthesis/activation of regulatory and/or inhibitory proteins, such as the phosphorylases which, in the case of TK, interrupts the intracellular signaling process by dephosphorylation (Fig. 1).

The cell communication system is made up of different “signaling pathways”, in which PK participate according to the objective of the signaling and the cell subpopulation they are in. To understand and describe the signaling process or cascade, the terms “upstream” and “downstream” are used. The literal translation of these 2 terms in Spanish would be “corriente arriba” and “corriente abajo”, analogy of the flow of a current of water that is utilized to indicate the direction and position of the proteins within the intracellular signaling cascade. Thus, when we say that an action takes place upstream it means that it occurs in the direction of the cell membrane, like cell receptor recognition and binding. On the other hand, when we say that this action takes place downstream, it means that it occurs in the direction of the cell nucleus, like gene transcription. Thus, if we talk about a TK like *Janus kinase 3* (JAK-3), any component that it activates and/or stimulates, such as the cytokines that bind to the common γ chain, is upstream (above it in the signaling cascade) and any component that the enzyme itself activates or regulates, as, for example, the activation and development of T lymphocytes and natural killer (NK) cells and their homeostasis is downstream (beneath it in the signaling cascade). Table 1 provides a detailed list of the meanings of these terms and the abbreviations or acronyms of each of the proteins, genes and transcription factors described in this review.

The Most Relevant Intracellular Signaling Pathways in the Design of Therapeutic Strategies

“MAPK” Pathway

There are 3 large subfamilies of mitogen-activated protein kinase (MAPK): p38, extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK). p38 is a serine/threonine kinase, and the best characterized subfamily to date: it has 4 homologous isoforms, alpha (α), beta (β), gamma (γ) and delta (δ), all of which are products of different genes that catalyze the same reaction. The α and β isoforms are ubiquitous, whereas the γ isoform is found in skeletal muscle and the δ isoform in the pancreas, small intestine and testes. On the other hand, ERK and JNK have 2 and 3 isoforms, respectively.^{8,9} p38 and JNK are activated upstream by a number of stimuli, such as the Fas ligand (FasL), growth factors, proinflammatory cytokines, lipopolysaccharides (LPS), viral proteins and osmotic cellular stress in dendritic cells, neutrophils, macrophages and T and B lymphocytes. These enzymes regulate fundamental cellular processes that take place downstream, such as cell cycle regulation, apoptosis, cell aging and the production of cytokines such as IL-10. ERK is activated upstream by infectious agents, mitotic signals, growth factors, hormones and proinflammatory cytokines, and activates cytoskeletal protein synthesis, cell proliferation and cell differentiation downstream.^{8,10}




Fig. 1. Diagram of the intracellular signaling pathways MAPK, Syk–Btk and JAK–STAT.

This pathway is negatively regulated by MAPK kinases—MKK3 and MKK6—(*MAPK-3 and 6*) and by protein tyrosine phosphatases (PTP) of MAPK, like the so-called dual specificity protein phosphatase (DUSP). Likewise, IL-1-RA and IL-10 production limits the production of proinflammatory cytokines and prostaglandins signaled by the pathway.¹¹

Activated ERK, JNK and p38 are found in synovial tissue of patients with RA, demonstrating that they play an important role in inflammation and tissue damage in autoimmune diseases. Failures in the regulation of these signaling pathways induce changes in the innate and adaptive immune response, tumor cell proliferation, insulin resistance, and the development of neurological and/or degenerative diseases, failures in infection control and autoinmunidad.^{8,10} p38 is a key protein in the regulation of the proinflammatory response and, as such, was one of the first PK to be investigated as a therapeutic target in autoimmunity and inflammation.¹²

“Syk–Btk” Pathway

The Syk family comprises 2 members: zeta-chain-associated protein kinase 70 (ZAP70) and spleen tyrosine kinase (Syk).¹³ ZAP70 limits its expression to T lymphocytes and NK cells; in contrast, Syk is expressed on hematopoietic cells, mast cells and synoviocytes. Syk binds to the cytoplasmic region of receptors containing the immunoreceptor tyrosine-based activation motif [ITAM]), like macrophage Fcγ receptors, neutrophils, mast cells and T-cell receptor/B-cell receptor (TCR/BCR).¹⁴ In RA, it has been observed that Syk is activated in synoviocytes by

proinflammatory cytokines like tumor necrosis factor (TNF) and IL-1, which induce JNK activation and IL-6 and metalloproteinase (MMP) expression upstream.¹⁵ Likewise, the activation of Syk promotes IL-12 and IL-13 synthesis, as well as the processes of cell proliferation, differentiation, survival, degranulation and phagocytosis.¹⁶

The Btk family has 4 members: Bruton tyrosine kinase/phosphoinositide 3-kinase (Btk/PI3K), IL-2 inducible T-cell kinase/epithelial-to-mesenchymal transition/tyrosine-protein kinase (Itk/Emt/Tsk), bone marrow tyrosine kinase gene in chromosome X protein/endothelial/epithelial tyrosine kinase (Bmx/Etk) and Tyr protein kinase cytosolic enzymes (Tec).¹⁷ Btk is a TK that is expressed in all the hematopoietic cells and lymphocytes except T lymphocytes and mature plasma cells. It is fundamental in lymphopoiesis and is downstream from Syk in this signaling pathway. Antigen presentation to BCR, IL-6 and erythropoietin activate upstream enzymes of the proto-oncogene c-Src family (Src), which phosphorylate Syk and, subsequently, Btk. Their phosphorylation initiates a number of cell processes, such as proliferation, survival, migration, angiogenesis, antigen presentation and cytokine production.¹⁸

PI3K is a subfamily of lipid kinases grouped from I to IV. They can be activated by the Syk–Btk axis by toll-like receptors (TLR) and adhesion molecules. Class I PI3K act on phosphatidylinositol bisphosphate (PIP2), generating a second messenger, phosphatidylinositol trisphosphate (PIP3), which binds to Btk, inducing its phosphorylation by Syk and Lyn. These enzymes play an important role in leukocyte migration, mast cell degranulation and entry of calcium into the cell.¹⁹

Table 1
Abbreviations.

AMA	American Medical Association	Sociedad Médica Americana
APhA	American Pharmacists Association	Sociedad Americana de Farmacéuticos
AS	Ankylosing spondylitis	espondilitis anquilosante
ATF-2	Transcription factor 2 response to stress and DNA damage	factor de transcripción 2 que responde al estrés y al daño del ADN
ATP	Adenosine triphosphate	adenosina trifosfato
BCR	B cell receptor	receptor del linfocito B
Bcl-6	B-cell lymphoma 6 protein	proteína 6 del linfoma del linfocito B
Bcl-xl	B-cell lymphoma-extra large	proteína del linfoma del linfocito B gigantes
Bfl-1	BCL2 protein family from a human fetal liver	familia de proteínas BCL2 del hígado fetal humano
Bmx	Bone marrow tyrosine kinase gene in chromosome X protein	gen en el cromosoma X de la TC de la médula ósea
Btk	Bruton's tyrosine kinase or BPK (<i>B cell progenitor kinase</i>)	tirosina-cinasa de Bruton o cinasa del linfocito B progenitor
CD	Crohn's disease	enfermedad de Crohn
CD95	Apoptosis antigen 1 or Fas receptor	antígeno apoptótico 1 o receptor de FasL
CHMP	Committee for medicinal products for human use	Comité de medicamentos para uso humano
COX	Cyclooxygenase	ciclooxigenasa
CREB	cAMP response element-binding protein	proteína de unión a la respuesta de cAMP
DNA	Deoxyribonucleic acid	ácido desoxirribonucleico
down-stream	Down-stream	señalización hacia abajo en la cascada
DUSP	Dual specificity protein phosphatase gene	genes que codifican proteínas-fosfatasa que inactivan p38, JNK y ERK
Egr-1	Early growth response protein 1	proteína de respuesta temprana al crecimiento 1
Elk-1	E-26-like protein 1	proteína tipo E-26
EMA	European Medicines Agency	Agencia Europea del Medicamento
Emt	Epithelial-to-mesenchymal transition	transición del epitelio mesenquimal
ERK	Extracellular signal-regulated kinase	PC que regula señales extracelulares
Etk	Endothelial and epithelial tyrosine kinase	TC endotelial y epitelial
FasL	Fas ligand or CD95 ligand	ligando del receptor de Fas o CD95
FDA	Food and Drug Administration	Agencia reguladora de alimentos y medicamentos
GM-CSF	Granulocyte macrophage colony-stimulating factor	factor estimulante de colonias de granulocitos y monocitos
IBD	Inflammatory bowel disease	enfermedad intestinal inflamatoria
IL	Interleukin	interleucina
INN	International Nonproprietary Name	Programa internacional de nombres genéricos de la Organización Mundial de la Salud (OMS)
IFN	Interferon	interferón
ITAM	Immunoreceptor tyrosine-based activation motif	inmunorreceptores activadores que contienen tirosina
ITK	IL-2 Inducible T-cell Kinase	cinasa del linfocito T
ITP	Immune thrombocytopenic purpura	púrpura trombocitopénica autoinmune
JNK	c-Jun N-terminal kinase	PC que fosforila la proteína c-Jun
LPS	Lipopolysaccharide	lipopolisacáridos
Lyn	Lck/Yes related novel tyrosine kinase	TC asociadas Lck y Yes
MAPK	Mitogen activated protein kinase	PC activada por mitógenos
MAPKK	MAPK: mitogen activated protein kinase	PC activada por mitógenos que activan MAPK
MAPKKK	MAPKK: mitogen activated protein kinase	PC activada por mitógenos que activan MAPKK
MEF2C	Myocyte enhancer factor 2	factor potenciador de miocitos 2
MMP	Matrix metalloproteinase	metaloproteinasas
MSK-1/2	Mitogen- and stress-activated kinase 1 and 2	PC 1 y 2 activada por mitógenos y el estrés oxidativo
NFAT	Nuclear factor of activated T-cells	factor nuclear que regula la activación del linfocito T
NF-κB	Nuclear factor kappa-light-chain-enhancer of activated B cells	factor nuclear que regula la transcripción de las cadenas ligeras kappa (κ)
NK	Natural killer cells	linfocitos asesinos naturales
Oct-2	Transcription factor 2	factor de transcripción 2
Pax-6	Paired box protein 6	proteína pareada 6
PIAS	Protein inhibitor of activated STATs	proteína inhibidora de la transcripción de STAT
PIP 2 y 3	Phosphatidylinositol bi and trisphosphate	fosfatidil inositol bi y trifosfato
PI3K	Phosphatidylinositol 3 kinase	PC de fosfatidil inositol 3
PK	Protein kinase	proteína cinasa
PKC	Protein kinase C	proteína-cinasa C
PLC	Phospholipase C	fosfolipasa C
Pso	Psoriasis	psoriasis
PTEN	Phosphatase and tensin homolog	fosfatidilinositol-3,4,5-trisfosfato 3-fosfatasa
PTP	Protein tyrosine phosphatases	tirosinas-fosfatasa
RA	Rheumatoid arthritis	artritis reumatoide
RANKL	Receptor activator of NF-κB ligand	ligando del receptor activador del NF-κB
SHP-1	Src homology region 2 domain-containing phosphatase-1	fosfatasa 1 de las tirosinas-cinasa Src
RHOA	Ras homolog family member A	proteína GTPasa que regula la actina
SLE	Systemic lupus erythematosus	lupus eritematoso sistémico
SMKI	Small molecular weight kinase inhibitors	pequeñas moléculas inhibidoras de PC
SNP	Single nucleotide polymorphism	polimorfismo de solo un nucleótido
SOCS	Suppressors of cytokine signaling	supresor de la señalización de citocinas
Src	Proto-oncogene c-Src	PC que fosforila el protooncogen SRC
STAT	Signal transducer and activator of transcription	transductor de señal y activador de la transcripción
Syk	Spleen tyrosine kinase	tirosina-cinasa del bazo
TCR	T cell receptor	receptor del linfocito T
Tec	Tyr protein-kinases enzymes cytosolic	TC citosólica
TK	Tyrosine kinase	tirosina cinasa
TLR	Toll-like receptor	receptor tipo Toll
TNFα	Tumor necrosis factor alpha	factor de necrosis tumoral alfa

Table 1 (Continued)

Tsk	T-cell signaling protein	proteína señalizadora del linfocito T
UC	Ulcerative colitis	colitis ulcerosa
up-stream	Up-stream	señalización arriba en la cascada de señalización
USAN	United States Adopted Names	Comisión americana encargada de asignar los nombres genéricos a nuevos fármacos
USP	United States Pharmacopeial Convention	Convención farmacopea de Estados Unidos de América
UV	Ultraviolet light	radiación ultravioleta
ZAP70	Zeta-chain-associated protein kinase 70 kDa	proteína asociada a la cadena zeta de 70 kilo-dalton

Downstream activation of these enzymes promotes the activation of other pathways that regulate inflammation, like MAPK (p38, ERK1/2), phosphoinositide 3-kinase (PI3K), phospholipase C (PLC) and transcription factors, such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) and nuclear factor of activated T-cells (NFAT). NF- κ B is an important protein complex comprised by transcription factors that are implicated in a large number of cell processes that are indispensable for cell survival and function, and NFAT regulates B lymphocyte activation, differentiation and maturation.²⁰

Tyrosine phosphatases, like Src homology region 2 domain-containing phosphatase (SHP)-1, SHP-2, protein kinase C (PKC) and phosphatase and tensin homolog (PTEN), regulate the enzyme activity of Syk, Btk and PI3K in cellular processes such as apoptosis, adhesion, migration and proliferation. Mutations in the Btk gene, like X-linked agammaglobulinemia (XLA), can block B lymphocyte differentiation and maturation, leaving the cells dysfunctional for antigen presentation. Likewise, the constitutive activation of this enzyme and signaling failures in the BCR–Btk axis promote the development and survival of aberrant B lymphocyte phenotypes. In murine lupus models, PI3K-deficiency has been found to reduce CD4+ T lymphocyte survival, antibody production, TNF- α , proteinuria and glomerulonephritis.²¹ Failures in the regulation of these enzymes can induce antibody-mediated and allergic diseases, like asthma and allergic rhinitis, as well as autoimmunity due to loss of tolerance and defects in antigen presentation by B lymphocytes, facilitating the development of diseases like RA, leukemia and cancer.^{22–24}

“JAK–STAT” Pathway

To date, 4 members of the JAK family have been identified: JAK-1, JAK-2, JAK-3 and TYK-2, which are ubiquitously expressed in all cells, with the exception of JAK-3, which is confined to hematopoietic cells. These TK are stimulated upstream by type I and type II cytokine receptors. JAK-1 is activated by cytokines that bind to receptors containing the common γ chain and transmembrane glycoprotein 130; JAK-2, by receptors containing transmembrane glycoprotein 130, IL-3 and interferon (INF)- γ ; JAK-3, by receptors containing the common γ chain; and, lastly, TYK-2 is stimulated by IL-12 and LPS.²⁵ These enzymes are structurally associated with the cytoplasmic region of cytokine receptors in the form of dimers or trimers. Each combination of JAK and/or TYK is modulated by specific stimuli and has a different function in cell signaling and, consequently, in the immune system. The dimers JAK-1/JAK-3, JAK-1/TYK-2, JAK-1/JAK-2 and JAK-2/TYK have different downstream functions characteristic of innate and adaptive immunity, whereas others, like the dimer JAK-2/JAK-2, regulate the maturation and differentiation of hematopoietic cell lines.^{26,27}

JAK/TYK phosphorylation induces the phosphorylation of the transcription factors, signal transducers and activators of transcription (STAT). These factors constitute a family with 7 members: STAT 1, 2, 3, 4, 5a, 5b and 6, which are found downstream in the signaling cascade and are associated with homodimers or heterodimers that, having been phosphorylated by JAK, dimerize and translocate to

the nucleus, where they bind to the target genes, increasing or repressing gene transcription and cell function.²⁸

Mutations in these enzymes or defects in the signaling have been associated with the development of myeloproliferative, autoimmune and inflammatory disorders.^{29,30} Genomic association studies have described the role of certain receptor, cytokine and enzyme genes associated with each of these JAK/TYK dimers and/or trimers and the susceptibility to developing allergies and different autoimmune and inflammatory diseases. For example, the signaling of the dimer JAK-1/TYK-2 by IFN- α is associated with Pso and IBD; JAK-2/TYK-2 with IL-12 and IL-23 in Behçet's disease, RA, SLE, Pso, IBD and AS; and the trimer JAK-1/JAK-2/TYK-2 with IL-6 stimulation and susceptibility to developing IBD.²⁸

This signaling pathway is regulated by different proteins, such as suppressors of cytokine signaling (SOCS), protein inhibitor of activated STAT (PIAS) and/or the tyrosine phosphatases SHP-1 and SHP-2, which block the binding of the STAT to DNA. This signaling pathway also regulates and is regulated by other signaling pathways, such as PI3K, MAPK and NF- κ B.^{25,31}

Challenges of the Development of Tyrosine Kinase Inhibitors

Autoimmune and inflammatory diseases are a group of chronic diseases in which, despite the availability of a number of therapeutic options, a percentage of patients do not respond adequately, probably due to the complexity of the immune system, as well as to the characteristics of each disease, of the drug and of the patient him- or herself. For all these reasons, it is still a challenge to select the appropriate therapeutic targets for the development of new drugs that increase the therapeutic options when the conventional and biologic therapies presently approved have failed. In recent decades, we have seen the development of a number of monoclonal antibodies to cytokines and cytokine receptors characteristic of the extracellular matrix or located in the cell membrane. For this reason, and due to the fact that JAK–STAT are pleiotropic enzymes that participate in the intracellular signaling of multiple cytokines, TK inhibitors have been developed as a new, more specific and effective therapeutic option in the inhibition of each disease process.²⁶

The main advantage of these small molecular weight kinase inhibitors (SMKI) is their oral administration versus the subcutaneous or intravenous administration of the monoclonal antibodies. This administration route facilitates adherence and increases the willingness of patients to receive the treatment, and could reduce costs with respect to the existing drugs. This group of drugs is absorbed in the stomach and small intestine. In the liver, the cytochrome P450 system takes charge of its metabolism, in which the presence of genetic polymorphisms like the single nucleotide polymorphism (SNP), can alter the pharmacokinetics, bioavailability and efficacy of the active ingredient, as has been reported with another type of drugs metabolized by this system. The TK inhibitors block the site for the binding of TK to adenosine triphosphate (ATP). This point is critical in the development of these new drugs because it is indispensable that the block be selective; for the inhibition to be effective and specific, and to prevent the inhibition of multiple TK and an increase in the risk of toxicity and/or of secondary effects.

This group of drugs has been included in the category of antineoplastic agents and has been assigned the suffix *-itinib* (International Nonproprietary Name [INN]).³² The nomenclature utilized for assigning generic names follows the recommendations of an advisory committee of the American Medical Association and the American Pharmacist's Association (USAN, AM, USP, APHA).³³

Use and Perspectives of Tyrosine Kinase

The clinical success of selective tyrosine kinase inhibitors in the treatment of tumors and leukemias (colorectal, gastric and breast cancer, hepatocellular carcinoma, sarcoma, metastatic melanoma, acute lymphoblastic leukemia and chronic myeloid leukemia) approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) has led to an increase in preclinical and clinical trials and studies of therapeutic options for the treatment of autoimmune and inflammatory diseases (www.clinicaltrials.gov). It has also deepened our understanding of the role of TK in intracellular signaling and inflammation.³⁴

In murine models of RA treated with p38 (SB203580 and PH-797804), JNK (SP600125) and ERK (PD98059), a decrease in proinflammatory factors, such as prostaglandins, and in IL-10 and joint inflammation has been observed.^{35,36} A recent study reports that SP600125 inhibits MMP expression, reduces cartilage loss and increases the number of regulatory T lymphocytes, also in a murine model of RA.³⁷ Due to the limited efficacy observed with the use of JNK and ERK inhibitors, the existing studies focus on its use in autoimmune diseases. In IBD, the utilization of p38 inhibitors such as semapimod (Ferring Pharmaceuticals) reduces inflammatory activity in CD, although the response is less than satisfactory in severe forms.³⁸ Tests with the drug doramapimod (Boehringer Ingelheim) in RA, AS and CD resulted in a decrease in the production of proinflammatory cytokines by certain cell lines.^{39,40} Treatment with pamapimod (Hoffman-La Roche) was found to have little efficacy in RA, and was accompanied by a high rate of infections and skin conditions.^{41,42}

With respect to the inhibition of Syk, studies *in vitro* and in animal models of RA showed that, PRT062070 (cerdulatinib), an inhibitor of Syk and JAK-1/3, reduced inflammatory activity and synovitis resulting from the suppression of autoantibody production caused by the blocking of signaling and B lymphocyte activation.⁴³ A study involving 2 models of RA in mice treated with P505-15, a selective Syk inhibitor, corroborated its efficacy in blocking BCA signaling and activation and in inhibiting basophil activation via Fc γ .⁴⁴ In clinical trials, fostamatinib disodium (AstraZeneca-Rigel), a Syk inhibitor, is being evaluated in patients with SLE, Pso and autoimmune thrombocytopenia purpura. In animal models of RA, the prodrug fostamatinib (R-788) was shown to reduce proinflammatory IL and MMP production and delay joint destruction, probably due to its acting on T lymphocytes and osteoclasts.⁴⁵ On the other hand, it was seen to prevent renal damage and the development of skin lesions in a murine model of lupus.⁴⁶ However, despite these findings, and in a preliminary phase III study, fostamatinib was not superior to placebo in patients with RA who had had a poor response to biologic therapies.⁴⁷

Different Btk inhibitors, like dasatinib (Bristol-Myers Squibb), PCI-32765 (ibrutinib, Janssen Research & Development, LLC), CC-292 (azacitidine, Celgene Corporation) and GDC-0834, have been approved for the treatment of multiple myeloma, lymphoma and B-cell leukemia and are being evaluated in preclinical and clinical studies of RA and SLE. *In vitro* studies have demonstrated that inhibition of Btk reduces bone loss in murine models of receptor activator of NF- κ B ligand (RANKL)-induced osteoporosis, as well as autoantibody production, and delays the development of kidney disease in a murine model of lupus.^{48–50} In a model

of collagen-induced arthritis in rats, GDC-0834 promoted a reduction of joint inflammation.^{24,51} Moreover, in a murine model of lupus, a decrease in IgG deposits and in cell infiltrate and activation was observed when the mice were treated with the inhibitor RN-486.⁵²

PI3K inhibitors are being widely studied in hematopoietic disorders and solid tumors. In preclinical studies, molecules such as IC-87114 and CZC24832 reduced IL-17 production, blocking Th17 lymphocyte differentiation and osteocyte generation in murine models of RA. Another inhibitor of PI3K, AS-605240, reduced inflammation, neutrophil infiltrate and erosions. This same molecule increased survival and reduced autoantibody production and attenuated glomerulonephritis in a murine model of lupus.¹⁹

The results obtained with different molecules directed against the JAK enzymes have shown promise in different clinical trials for the treatment of Pso and RA, and the second generation of these molecules is defined as being more specific and effective as inhibitors. In models of RA treated with decernotinib (Vertex Pharmaceuticals Inc.), a molecule directed against JAK-3, there was a reduction in joint inflammation,⁵³ although preliminary clinical results revealed an increase in the risk of infections and in the transaminase levels.⁵⁴ ASP015K (Astellas Pharma Inc.), a JAK-3 inhibitor that, to a lesser extent, inhibits JAK-1 and JAK-2 as well, has promoted the reduction of the epidermis thickness and of cell proliferation in patients with Pso.⁵⁵ Baricitinib (Incyte and Eli Lilly Company), a JAK-1/JAK-2 inhibitor, has been found to reduce inflammatory activity and favor the preservation of cartilage and bone in a murine model.⁵⁶ Ruxolitinib (Incyte Corporation and Novartis) is an oral drug that inhibits JAK-1/JAK-2; approved for the treatment of proliferative disorders, its topical form is being evaluated for use in the treatment of Pso. The study of this molecule in murine models showed that it promoted a decrease in STAT-3 phosphorylation and, with that, the reduction of edema, lymphocyte infiltration and psoriatic plaques.⁵⁷ Results in clinical trials indicated that this drug is well tolerated and is effective in the treatment of Pso.⁵⁸ On the other hand, tofacitinib (Pfizer) is the only TK inhibitor that is commercially available in the United States and other countries for the treatment of RA. It is a functional inhibitor specific for JAK-3 that also inhibits JAK-1 and, to a lesser extent, JAK-2.^{59,60} In preclinical studies, this inhibitor was found to reduce the levels of chemokines, interleukins, acute phase reactants and RANKL, promoting the reduction of bone reabsorption mediated by osteoclasts and inflammation.⁶¹ It has also been seen to inhibit the proinflammatory response of Th1 and Th17⁶² and prevent cartilage damage in animal models.⁶³

In more recent studies, it has been observed that, in RA patients treated with tofacitinib, there is an inhibition of the proliferation of CD4⁺ T lymphocytes without affecting their absolute number on the periphery. Moreover, it has been found that, before treatment, a small number of CD8⁺ T lymphocytes are correlated with the development of secondary effects during the treatment in patients with RA.⁶⁴ Given the efficacy of tofacitinib in the treatment of RA, phase III clinical trials are now underway in Pso, as well as UC, CD and AS.

A summary of the major clinical trials carried out in autoimmune and inflammatory diseases is provided in Table 2. Despite the challenge posed by the development of these inhibitors when compared with monoclonal antibodies—that is, intracellular proteins versus extracellular proteins, the secondary effects reported do not seem to differ from those observed up to now with biologic therapies: neutropenia, high rates of infection, hepatotoxicity and elevated liver enzymes, altered thyroid function, fatigue, hypertension, skin rashes, delayed wound closure, myelosuppression, diarrhea, elevated creatinine levels and hyperlipidemia, among others. For this reason, work is currently underway to develop inhibitory molecules with greater specificity and an effect better aimed at each disease.

Table 2
Protein Kinase Inhibitors Evaluated for the Treatment of Autoimmune and Inflammatory Diseases.

Therapeutic target	Drug/molecule	Laboratory	Clinical trial	Indication	Status
p38	Dilmapimod/SB-681323	Glaxo Smith Kline	II	RA	Terminated
	Semapimod/CNI-1493	Ferring Pharmaceuticals	II	CD ³⁸	Terminated
	Pamapimod/RO4402257	Hoffman-La Roche	II	RA ⁴²	Terminated
	PH-797804	Pfizer	II	RA ³⁵	Terminated
	VX-702	Vertex Pharmaceuticals Inc.	II	RA ⁶⁵	Terminated
	BMS-582949 ⁶⁶	Bristol-Myers Squibb	I	Pso	Terminated
			II	RA	
	Talmapimod/SCIO-469	Scios Inc.	II	RA ⁶⁷	Terminated
	ARRY-371797	Array BioPharma	II	RA and AS	Terminated
	Doramapimod/BIRB-796	Boehringer Ingelheim	Ila	RA, Pso and CD ³⁹	Terminated
Syk	Fostamatinib disodium/R935788	AstraZeneca-Rigel	II	SLE	
			III	RA ^{47,68}	Suspended
			III	ITP	Recruiting
Btk	Azacitidine/CC-292	Celgene Corporation	II	RA	Recruiting
JAK-1	GSK2586184	Glaxo Smith Kline	I	UC	Suspended
			II	SLE and Pso	Terminated
			II	RA, CD ⁶⁹	Recruiting
	Filgotinib/GLPG0634	Galapagos NV.	II		
	PF-04965842	Pfizer	II	Pso	Recruiting
JAK-2	AC430	Ambit Biosciences Co.	I	RA	Terminated
JAK-3	ASP015K/JNJ-54781532	Astellas Pharma Inc.	II	RA and Pso ⁵⁴	Recruiting
			II and III	RA ⁵³	Terminated
JAK-3 and Syk	R-333	Rigel Pharmaceuticals	II	SLE	Terminated
JAK-1/2	Ruxolitinib/INCB-018424	Incyte Co. and Novartis	II	RA and Pso ⁵⁸	Terminated
			II	Pso	Terminated
			III	RA ⁷⁰	Recruiting
	Baricitinib/INCB-28050-LY-3009104	Incyte and Eli Lilly Co.			
JAK-1/3	Tofacitinib/CP-690-550	Pfizer	Approved by FDA	RA ^{59,60}	Recruiting
			II	AS and CD ⁷¹	Recruiting
			III	Pso and UC ⁷²	Recruiting
JAK-2/3	Lestauritinib/CEP-701	Cephalon	II	Pso	Terminated

Tofacitinib, the Only Tyrosine Kinase Inhibitor Approved for Use in Rheumatoid Arthritis: Present Situation in Europe

In November 2012, the FDA granted approval to tofacitinib (Xeljanz[®]) for the treatment of moderate to severe RA in adults who have had an inadequate response or intolerance to methotrexate (MTX). According to its technical specifications, tofacitinib is administered orally, at doses of 5 mg twice daily, as monotherapy or in combination with MTX or other synthetic drugs. It should not be used in combination with biologic therapies or immunosuppressive agents such as azathioprine and cyclosporine. At the present time, in addition to the United States, tofacitinib has been approved for the treatment of RA in several countries, including Japan, Russia, Canada and Switzerland.

As for the European Community, in April 2013, the Committee for Medicinal Products for Human Use (CHMP) of the EMA considered that, despite the evidence of a reduction in the signs and symptoms of RA and an evident improvement in the physical function of these patients, the benefit was not sufficient to outweigh the associated secondary effects, such as serious infections, gastrointestinal perforations and cancer, despite the fact that the dossier presented to the FDA was the same as that presented to the EMA. Therefore, due to the uncertainty caused by the magnitude of the risks and their management in clinical practice, it was considered that making it commercially available was not worthwhile in terms of the benefits obtained with the treatment (EMA/CHMP/425279/2013, Procedure No. EMA/H/C/002542/0000). In view of this, the company requested a reevaluation of the risks/benefits of the drug, and the group of experts, in accordance with article 12 of Regulation (EC) no. 726/2004, ruled that the risk/benefit ratio of tofacitinib was inadequate or had not been convincingly demonstrated and, thus, refused once again to authorize that it be marketed

(EMA/CHMP/425279/2013). However, since this drug has been commercially available in the United States for 2 years, we hope that we will soon have evidence from clinical practice to corroborate the results obtained in the clinical trials. On the other hand, tofacitinib continues to be evaluated in different clinical trials for its use in other conditions involving autoimmunity and inflammation, to take position as a new therapeutic option in the treatment of this group of diseases.

Conclusion

The use of drugs that inhibit PK, like TK, could change the therapeutic approach in diseases involving failures in the regulation of the immune system, due to the ubiquity of these molecules in the process of intracellular signaling and, thus, in their effect on autoimmune and inflammatory processes. This could benefit those patients in whom multiple treatments have failed because of a loss of efficacy and secondary effects. Likewise, the introduction of these molecules that are administered orally would change patient adherence and reduce the cost associated with the treatment compared to the administration of monoclonal antibodies. However, the anything but promising results with some of these PK inhibitors have shown us that not all the intracellular signaling pathways are susceptible to being blocked to provide beneficial clinical effects. As new results in clinical practice concerning the use of these therapeutic targets are obtained, it will be possible to identify those signaling pathways that are most appropriate for the goal of obtaining a proper balance between the desired clinical efficacy and the adverse effects. In this respect, and in light of the evidence that is being obtained with the use of inhibitors of the JAK kinases, like tofacitinib, the JAK-STAT pathway is seen as one of the main therapeutic targets for the development of new drugs and the treatment of diseases of the immune system.

Ethical Disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflicts of Interest

Lara Valor has received professional fees from Abbvie, Bristol-Myers Squibb, Pfizer, Roche Farma, UCB Pharma and Merck Sharp & Dohme Limited (MSD). Diana Hernández-Flórez declares that she has no conflicts of interest.

Acknowledgments

The authors thank Drs. Luis Carreño Pérez, Francisco Javier López Longo (Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain) and Gustavo Centeno Soto (Department of Clinical Pharmacology, Hospital Puerta de Hierro, Madrid, Spain) for their critical reading of this manuscript.

References

- Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. *Nat Rev Rheumatol.* 2013;9:154–63.
- Patterson H, Nibbs R, McInnes I, Siebert S. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. *Clin Exp Immunol.* 2014;176:1–10.
- Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. *Science.* 2002;298:1912–34.
- Knight JD, Pawson T, Gingras AC. Profiling the kinome: current capabilities and future challenges. *J Proteomics.* 2013;81:43–55.
- Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. *Nat Rev Drug Discov.* 2009;8:709–23.
- Lodish MB. Clinical review: kinase inhibitors: adverse effects related to the endocrine system. *J Clin Endocrinol Metab.* 2013;98:1333–42.
- Schlessinger J. Cell signaling by receptor tyrosine kinases. *Cell.* 2000;103:211–25.
- Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. *Microbiol Mol Biol Rev.* 2004;68:320–44.
- Bonilla-Hernán MG, Miranda-Carús ME, Martín-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. *Rheumatology (Oxford).* 2011;50:1542–50.
- Korhonen R, Moilanen E. Mitogen-activated protein kinase phosphatase 1 as an inflammatory factor and drug target. *Basic Clin Pharmacol Toxicol.* 2014;114:24–36.
- Lang R, Hammer M, Mages J. DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. *J Immunol.* 2006;177:7497–504.
- López-Santalla M, Salvador-Bernáldez M, González-Alvaro I, Castañeda S, Ortiz AM, García-García MI, et al. Tyr³²³-dependent p38 activation is associated with rheumatoid arthritis and correlates with disease activity. *Arthritis Rheum.* 2011;63:1833–42.
- Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. *Drug Discov Today.* 2010;15:517–30.
- Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. *Nat Rev Immunol.* 2013;13:578–91.
- Hammaker D, Firestein GS. Go upstream, young man: lessons learned from the p38 saga. *Ann Rheum Dis.* 2010;69:177–82.
- Siraganian RP, Zhang J, Suzuki K, Sada K. Protein tyrosine kinase Syk in mast cell signaling. *Mol Immunol.* 2002;38:1229–33.
- Qiu Y, Kung HJ. Signaling network of the Btk family kinases. *Oncogene.* 2000;19:5651–61.
- Tan SL, Liao C, Lucas MC, Stevenson C, DeMartino JA. Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. *Pharmacol Ther.* 2013;138:294–309.
- Foster JG, Blunt MD, Carter E, Ward SG. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. *Pharmacol Rev.* 2012;64:1027–54.
- Dáňová K, Klapetková A, Kayserová J, Šedivá A, Špišek R, Jelínková LP. NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment. *Oncotarget.* 2015;6:14123–38.
- So L, Fruman DA. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. *Biochem J.* 2012;442:465–81.
- Puri KD, di Paolo JA, Gold MR. B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. *Int Rev Immunol.* 2013;32:397–427.
- Scott DL. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis. *Drugs.* 2011;71:1121–32.
- Vargas L, Hamasy A, Nore BF, Smith CI. Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. *Scand J Immunol.* 2013;78:130–9.
- Schindler C, Levy DE, Decker T. JAK–STAT signaling: from interferons to cytokines. *J Biol Chem.* 2007;282:20059–63.
- Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. *J Med Chem.* 2014;57:5023–38.
- Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. *Growth Factors.* 2012;30:88–106.
- O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. *Immunity.* 2012;36:542–50.
- Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. *Cancer Cell.* 2008;14:335–43.
- Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. *Curr Opin Pharmacol.* 2012;12:464–70.
- Shuai K. Regulation of cytokine signaling pathways by PIAS proteins. *Cell Res.* 2006;16:196–202.
- WHO. International Nonproprietary Names (INN) Working Group Meeting on Nomenclature for Monoclonal Antibodies (mAb). Meeting Report. Geneva, Switzerland: World Health Organization; 2008.
- WHO. International Nonproprietary Names (INN) for Biological and Biotechnological Substances. Geneva, Switzerland: World Health Organization; 2012.
- Okamoto H, Kobayashi A. Tyrosine kinases in rheumatoid arthritis. *J Inflamm (Lond).* 2011;8:21.
- Hope HR, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL, et al. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. *J Pharmacol Exp Ther.* 2009;331:882–95.
- Hammaker D, Boyle DL, Topolewski K, Firestein GS. Differential regulation of anti-inflammatory genes by p38 MAP kinase and MAP kinase kinase 6. *J Inflamm (Lond).* 2014;11:14.
- Scheptekin IA, Kirpotina LN, Hammaker D, Kochetkova I, Khlebnikov AI, Lyakhov SA, et al. Anti-inflammatory effects and joint protection in collagen-induced arthritis after treatment with IQ-1S, a selective c-Jun N-terminal kinase inhibitor. *J Pharmacol Exp Ther.* 2015;353:505–16.
- Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, et al. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. *Gut.* 2010;59:760–6.
- Schreiber S, Feagan B, d'Haens G, Colombel JF, Geboes K, Yurcov M, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. *Clin Gastroenterol Hepatol.* 2006;4:325–34.
- Ryoo S, Choi J, Kim J, Bae S, Hong J, Jo S, et al. BIRB 796 has distinctive anti-inflammatory effects on different cell types. *Immune Netw.* 2013;13:283–8.
- Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. *Curr Opin Rheumatol.* 2010;22:330–5.
- Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. *Arthritis Rheumatol.* 2009;60:335–44.
- Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, et al. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. *J Pharmacol Exp Ther.* 2014;351:538–48.
- Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. *J Pharmacol Exp Ther.* 2012;340:350–9.
- Bajpai M. Postmatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. *IDrugs.* 2009;12:174–85.
- Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. *Arthritis Rheumatol.* 2008;58:1433–44.
- Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. *Arthritis Rheumatol.* 2011;63:337–45.
- Shinohara M, Chang BY, Buggy JJ, Nagai Y, Kodama T, Asahara H, et al. The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. *Bone.* 2014;60:8–15.

49. Honigberg LA, Smith AM, Sirisawad M, Verner E, Louny D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. *Proc Natl Acad Sci U S A.* 2010;107:13075–80.
50. Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. *J Pharmacol Exp Ther.* 2013;346:219–28.
51. Liu L, di Paolo J, Barbosa J, Rong H, Reif K, Wong H. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. *J Pharmacol Exp Ther.* 2011;338:154–63.
52. Mina-Osorio P, LaStant J, Keirstead N, Whittard T, Ayala J, Stefanova S, et al. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase. *Arthritis Rheum.* 2013;65:2380–9.
53. Mahajan S, Hogan JK, Shlyakhter D, Oh L, Salituro FG, Farmer L, et al. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. *J Pharmacol Exp Ther.* 2015;353:405–14.
54. Fleischmann RM, Damjanov NS, Kivitz AJ, Legedza A, Hoock T, Kinnman N. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. *Arthritis Rheumatol.* 2015;67:334–43.
55. Papp K, Pariser D, Catlin M, Wierz G, Ball G, Akinlade B, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. *Br J Dermatol.* 2015. <http://dx.doi.org/10.1111/bjd.13745>.
56. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. *J Immunol.* 2010;184:5298–307.
57. Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, Hertel D, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. *J Invest Dermatol.* 2011;131:1838–44.
58. Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. *J Am Acad Dermatol.* 2012;67:658–64.
59. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med.* 2012;367:495–507.
60. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. *J Rheumatol.* 2014;41:837–52.
61. LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. *Arthritis Rheum.* 2012;64:3531–42.
62. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsop JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). *J Immunol.* 2011;186:4234–43.
63. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. *Arthritis Res Ther.* 2008;10:R14.
64. Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, et al. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. *Rheumatology (Oxford).* 2014;53:914–8.
65. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. *Arthritis Rheum.* 2009;60:1232–41.
66. Liu C, Lin J, Wroblewski ST, Lin S, Hynes J, Wu H, et al. Discovery of 4-(5-(cyclopropylcarbonyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo [1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases. *J Med Chem.* 2010;53:6629–39.
67. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Braun E, et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. *J Rheumatol.* 2011;38:846–54.
68. Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheumatol.* 2014;66:3255–64.
69. Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of Filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. *Clin Pharmacokinet.* 2015;54:859–74.
70. Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. *Ann Rheum Dis.* 2015;74:333–40.
71. Panés J, Su C, Bushmakina AG, Cappelleri JC, Mamolo C, Healey P. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. *BMC Gastroenterol.* 2015;15:14.
72. Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. *Lancet.* 2015;62113–9, pii: S0140-6736(14).